A Phase Ib/II Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Patients With Malignant Pleural Effusion
Latest Information Update: 19 Apr 2022
At a glance
- Drugs Bevacizumab (Primary) ; Camrelizumab (Primary)
- Indications Cancer; Malignant pleural effusion
- Focus Adverse reactions; Therapeutic Use
- 19 Apr 2022 New trial record